LGALS3 and Myocardial fibrosis: Circulating galectin-3 has been suggested as a potential biomarker for diabetic nephropathy progression and cardiovascular disease prognosis linked to myocardial fibrosis, tissue remodelling, and heart failure development [53,54,55].